Engineered tRNAs efficiently suppress CDKL5 premature termination codons.

Area of Science:

• Genetics
• Molecular Biology
• Neuroscience

Background:

• CDKL5 deficiency disorder (CDD) is a severe neurodevelopmental disorder with no cure, primarily managed through seizure control.
• Pathogenic variants in the CDKL5 gene, crucial for brain development, cause CDD.
• Nonsense mutations account for a significant portion of CDD cases, presenting an opportunity for readthrough therapies.

Purpose of the Study:

• To investigate Anticodon-edited tRNAs (ACE-tRNAs) as a novel readthrough strategy for CDKL5 deficiency disorder (CDD).
• To evaluate the efficacy of ACE-tRNAs in restoring functional CDKL5 protein synthesis from nonsense variants.
• To compare ACE-tRNA therapy with previous drug-mediated readthrough approaches.

Main Methods:

• Utilized cell transfection models expressing various CDKL5 nonsense variants.
• Employed ACE-tRNAs designed to target and correct premature nonsense codons in CDKL5 mRNA.
• Assessed the synthesis, localization, and catalytic activity of the recoded CDKL5 kinase.

Main Results:

• ACE-tRNAs efficiently restored the synthesis of full-length CDKL5 kinase in cells with nonsense mutations.
• The recoded CDKL5 protein exhibited correct cellular localization and retained catalytic activity.
• Drug-mediated readthrough, while suppressing nonsense codons, resulted in a hypomorphic kinase, limiting its therapeutic value.

Conclusions:

• ACE-tRNAs represent a viable alternative readthrough strategy for CDD caused by nonsense mutations.
• This tRNA-based approach successfully restores functional CDKL5 protein, unlike previous pharmacological methods.
• Further investigation is warranted to assess the therapeutic potential of ACE-tRNAs for correcting the CDD phenotype.